Ulrich C Bang1, Tomohiro Watanabe2, Flemming Bendtsen1,3. 1. Gastrounit, Medical Section, University Hospital of Hvidovre, Hvidovre. 2. Faculty of Health and Medical Sciences, University of Copenhagen, Copenhagen, Denmark. 3. Department of Gastroenterology and Hepatology, Faculty of Medicine, Kindai University, Higashiosaka, Japan.
Abstract
OBJECTIVES: Chronic pancreatitis (CP) is associated with a shortened life expectancy. Statins have anti-inflammatory properties and we aimed to evaluate the association between the use of statins and the risk of death, progression of CP, and pancreatic cancer in patients with CP. PATIENTS AND METHODS: We carried out a nested case-cohort study and included patients with CP. We used claims of proton pump inhibitors as an active comparator. Patients with cirrhosis or cancer were excluded. We evaluated the exposure on the basis of pharmacy claims of statins. We used propensity score matching with a statins : nonstatins ratio of 1 : 1. RESULTS: A total of 4807 patients were eligible for propensity score matching; 33% were women and the mean (SD) age at cohort entry was 56 (10) years. During follow-up, a total of 2073 (43%) patients had died and the risk of death was significantly lower among patients using statins versus no statins among 678 matched patients [hazard ratio (HR) 0.64; 95% confidence interval (CI): 0.49-0.83]. Use of statins versus no statins was associated with decreased progression of CP, with an HR of 0.21 (95% CI: 0.17-0.26). Pancreatic cancer occurred in 117 (2.4%) patients and we found a lower risk of pancreatic cancer in statin-treated patients compared with no statins, with a HR of 0.21 (95% CI: 0.06-0.70). CONCLUSION: In this nationwide study, we found lower risks of mortality, disease progression, and pancreatic cancer in patients with CP using statins. The study is limited by its retrospective design, but supports the hypothesis that statins may affect the course of CP.
OBJECTIVES:Chronic pancreatitis (CP) is associated with a shortened life expectancy. Statins have anti-inflammatory properties and we aimed to evaluate the association between the use of statins and the risk of death, progression of CP, and pancreatic cancer in patients with CP. PATIENTS AND METHODS: We carried out a nested case-cohort study and included patients with CP. We used claims of proton pump inhibitors as an active comparator. Patients with cirrhosis or cancer were excluded. We evaluated the exposure on the basis of pharmacy claims of statins. We used propensity score matching with a statins : nonstatins ratio of 1 : 1. RESULTS: A total of 4807 patients were eligible for propensity score matching; 33% were women and the mean (SD) age at cohort entry was 56 (10) years. During follow-up, a total of 2073 (43%) patients had died and the risk of death was significantly lower among patients using statins versus no statins among 678 matched patients [hazard ratio (HR) 0.64; 95% confidence interval (CI): 0.49-0.83]. Use of statins versus no statins was associated with decreased progression of CP, with an HR of 0.21 (95% CI: 0.17-0.26). Pancreatic cancer occurred in 117 (2.4%) patients and we found a lower risk of pancreatic cancer in statin-treated patients compared with no statins, with a HR of 0.21 (95% CI: 0.06-0.70). CONCLUSION: In this nationwide study, we found lower risks of mortality, disease progression, and pancreatic cancer in patients with CP using statins. The study is limited by its retrospective design, but supports the hypothesis that statins may affect the course of CP.
Authors: Linara Gabitova-Cornell; Aizhan Surumbayeva; Suraj Peri; Janusz Franco-Barraza; Diana Restifo; Nicole Weitz; Charline Ogier; Aaron R Goldman; Tiffiney R Hartman; Ralph Francescone; Yinfei Tan; Emmanuelle Nicolas; Neelima Shah; Elizabeth A Handorf; Kathy Q Cai; Alana M O'Reilly; Ido Sloma; Rachel Chiaverelli; Richard A Moffitt; Vladimir Khazak; Carolyn Y Fang; Erica A Golemis; Edna Cukierman; Igor Astsaturov Journal: Cancer Cell Date: 2020-09-24 Impact factor: 31.743
Authors: Jin Ho Choi; Sang Hyub Lee; Gunn Huh; Jung Won Chun; Min Su You; Woo Hyun Paik; Ji Kon Ryu; Yong-Tae Kim Journal: Cancer Med Date: 2019-10-21 Impact factor: 4.452